C3 Glomerulopathy | Zendy

Nicholas MedjeralThomas | Zendy; Michelle M. O’Shaughnessy | Zendy; John O’Regan | Zendy; Carol Traynor | Zendy; Michael Flanagan | Zendy; Limy Wong | Zendy; Chia Wei Teoh | Zendy; Atif Awan | Zendy; Mary Waldron | Zendy; Tom Cairns | Zendy; Patrick O’Kelly | Zendy; Anthony Dorman | Zendy; Matthew C. Pickering | Zendy; Peter J. Conlon | Zendy; H. Terence Cook | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

C3 Glomerulopathy

Author(s) -

Nicholas MedjeralThomas,

Michelle M. O’Shaughnessy,

John O’Regan,

Carol Traynor,

Michael Flanagan,

Limy Wong,

Chia Wei Teoh,

Atif Awan,

Mary Waldron,

Tom Cairns,

Patrick O’Kelly,

Anthony Dorman,

Matthew C. Pickering,

Peter J. Conlon,

H. Terence Cook

Publication year - 2013

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.04700513

Subject(s) - medicine , glomerulopathy , cohort , population , kidney disease , glomerulonephritis , gastroenterology , end stage renal disease , pathology , kidney , disease , environmental health

The term C3 glomerulopathy describes renal disorders characterized by the presence of glomerular deposits composed of C3 in the absence of significant amounts of Ig. On the basis of electron microscopy appearance, subsets of C3 glomerulopathy include dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). The full spectrum of histologic change observed in C3 glomerulopathy has yet to be defined and pathologic predictors of renal outcome within this patient population remain largely unknown. This study thus characterized a large C3 glomerulopathy cohort and identified clinicopathologic predictors of renal outcome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research